Evidence map›Paper›PMID 39739165›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025

3-Hydroxybenzoic acid inhibits the virulence attributes and disrupts biofilm production in clinical isolates of Acinetobacter baumannii.

Naji Naseef Pathoor, Pitchaipillai Sankar Ganesh, Abdul R Anshad, Rajesh Kanna Gopal, Esaki Muthu Ponmalar, Suvaiyarasan Suvaithenamudhan, Parthiban Rudrapathy, Esaki M Shankar

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Naji Naseef PathoorDepartment of Microbiology, Centre for Infectious Diseases, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University (Deemed to be University), Chennai, 600 077, Tamil Nadu, India.
Pitchaipillai Sankar GaneshDepartment of Microbiology, Centre for Infectious Diseases, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University (Deemed to be University), Chennai, 600 077, Tamil Nadu, India. p_sankarganesh@hotmail.com.
Abdul R AnshadInfection and Inflammation, Department of Biotechnology, School of Integrative Biology, Central University of Tamil Nadu, Thiruvarur, Tamil Nadu, 610 005, India.
Rajesh Kanna GopalDepartment of Microbiology, Centre for Infectious Diseases, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University (Deemed to be University), Chennai, 600 077, Tamil Nadu, India.
Esaki Muthu PonmalarSri Sairam Siddha Medical College and Research Centre, West Tambaram, Chennai, 600 044, Tamil Nadu, India.
Suvaiyarasan SuvaithenamudhanDepartment of Research, Meenakshi Academy of Higher Education and Research (MAHER) (Deemed to be University), Chennai, 600 078, India.
Parthiban RudrapathyMicrobiology Division, Department of Clinical Laboratory Services and Translational Research, Malabar Cancer Centre (Post Graduate Institute of Oncology Sciences and Research), Thalassery, 670 103, Kerala, India.
Esaki M ShankarInfection and Inflammation, Department of Biotechnology, School of Integrative Biology, Central University of Tamil Nadu, Thiruvarur, Tamil Nadu, 610 005, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAcinetobacter baumannii (A. baumannii) is an emerging global public health threat owing to its ability to form biofilms. Here, we evaluated 3-hydroxybenzoic acid (3-HBA), a promising organic compound, for its ability to disrupt biofilm formation and virulence attributes in clinical isolates of A. baumannii. MATERIALS AND

methodsThe effect of 3-HBA on A. baumannii was assessed by determining the minimum inhibitory concentration (MIC) and certain other in vitro investigations viz., extracellular polymeric substance (EPS) estimation, crystal violet staining assay, motility assay, and the hydrogen peroxide (H

resultsAt a sub-inhibitory concentration of 0.078 mg/mL, 3-HBA reduced biofilm formation in A. baumannii LSAB-04 and A. baumannii LSAB-06 by 61.22% and 59.21%, respectively, and decreased EPS production by 64% in LSAB-04 and 58.31% in LSAB-06. Microscopic examination confirmed significant biofilm dispersion. 3-HBA also significantly impaired swarming motility and increased their sensitivity to H

conclusionOur findings underscore the likely role of 3-HBA as a promising A. baumannii biofilm-disrupting agent. Further, by downplaying against the virulence factors of A. baumannii, 3-HBA could be a compelling alternative to conventional antibiotics that however requires to be investigated.

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsBiofilmsHydroxybenzoatesAcinetobacter InfectionsCell SurvivalHumansHydrogen PeroxideMCF-7 CellsMicrobial Sensitivity TestsVirulenceAnti-Bacterial AgentsHydrogen PeroxideHydroxybenzoates3-hydroxy benzoic acidA. baumanniiBiofilmQuorum sensing

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.